Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518827 | 0.89 | VCAM1 (0.62) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL11583829 | 0.89 | GPR35 (0.56) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL15823361 | 0.87 | ALDH1A1 (0.50) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL16023094 | 0.79 | VCAM1 (0.38) | ALDH1A1VCAM1HSD17B10KMT2AMAPT | |
| SCHEMBL6431969 | 0.79 | ALDH1A1 (0.64) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL14318562 | 0.77 | ALDH1A1 (0.47) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL14318545 | 0.77 | ALDH1A1 (0.47) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL14306409 | 0.76 | ALDH1A1 (0.46) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL11939743 | 0.76 | VCAM1 (0.60) | ALDH1A1VCAM1HSD17B10GPR35XDH | |
| SCHEMBL16236822 | 0.76 | VCAM1 (0.60) | ALDH1A1VCAM1HSD17B10GPR35XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428289-B | As the triazole compounds of antivirotic | 弗·哈夫曼-拉罗切有限公司 | 2017-06-23 | — | — | CN | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2964637-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2964637-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-08-25 | — | — | US | disclosed |
| WO-2005034869-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
| US-4602041-A | TREATMENT OF DIARRHEA | BEECHAM GROUP P.L.C. (GB) | 1986-07-22 | — | — | US | disclosed |
| EP-0087218-B1 | GUANIDINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1985-05-02 | — | — | EP | disclosed |
| EP-0087218-A1 | Guanidine derivatives | BEECHAM GROUP PLC (GB) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ALDH1A1 190/4885VCAM1 1378/4885HSD17B10 1495/4885 |
| US-20050187230-A1 | Compounds and compositions as protein kinase inhibitors | FYN, LCK, SRC | ALDH1A1 4740/4885VCAM1 2321/4885HSD17B10 4667/4885 |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | ALDH1A1 115/4885VCAM1 4082/4885HSD17B10 291/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | ALDH1A1 89/4885VCAM1 4131/4885HSD17B10 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.